TD Cowen Remains Bullish on Roivant Sciences Ltd. (ROIV) – Here’s Why

Roivant Sciences Ltd. (NASDAQ:ROIV) is 1 of the champion healthcare stocks nether $50 to put in. TD Cowen maintained a bullish outlook connected Roivant Sciences Ltd. (NASDAQ:ROIV) connected February 6, revising the terms people connected the banal to $38 from $28 and maintaining a Buy rating. The standing update came the aforesaid time Roivant Sciences Ltd. (NASDAQ:ROIV) announced affirmative Phase 2 results for brepocitinib successful cutaneous sarcoidosis (CS) and reported its fiscal results for Q3 ended December 31, 2025.

Roivant Sciences Ltd. (NASDAQ:ROIV) reported that brepocitinib 45 mg considerably improved cutaneous sarcoidosis illness enactment and exhibited rapid, deep, and sustained improvements crossed each different efficacy endpoints measured with a accordant information profile. Management further stated that an NDA was submitted to the FDA for brepocitinib successful dermatomyositis (DM), with topline information from Phase 3 studies successful non-infectious uveitis (NIU) anticipated successful H2 of calendar twelvemonth 2026. Roivant Sciences Ltd. (NASDAQ:ROIV) is continually exploring different indications for brepocitinib.

In addition, the institution reported $4.5 cardinal successful consolidated cash, currency equivalents, restricted cash, and marketable securities arsenic of December 31, 2025, supporting currency runway into profitability.

Roivant Sciences Ltd. (NASDAQ:ROIV) is simply a biopharmaceutical institution that develops transformative medicines. Its merchandise portfolio comprises Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which dainty psoriasis, atopic dermatitis, thyroid oculus disease, and different illnesses. Its merchandise candidates widen crossed assorted therapeutic areas, including oncology, immunology, dermatology, and hematology.

While we admit the imaginable of ROIV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.